Tarsus Pharmaceuticals Inc (NAS:TARS)
$ 28.93 1.38 (5.01%) Market Cap: 1.09 Bil Enterprise Value: 825.02 Mil PE Ratio: 0 PB Ratio: 3.97 GF Score: 60/100

Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 08:05PM GMT
Release Date Price: $13.74 (-3.98%)
Balaji Prasad
Barclays Investment Bank - Analyst

Good afternoon everyone. My name is Balaji Prasad. I'm the senior analyst for the specialty pharmaceuticals coverage. Continuing on with our afternoon session, we have with us the management from Tarsus. We've Leo Greenstein, the Chief Financial Officer of Tarsus. In this session, [we've around] around 5 minutes of presentation and around 20 minutes of Q&A. With that, over to you, Leo.

Leo Greenstein
Tarsus Pharmaceuticals, Inc. - CFO

Thank you. (technical difficulty) I'd like to discuss the legal disclaimer. And just make note that we're making forward-looking statements during today's presentation.

Tarsus is on its way towards being the leading eye care pharma leader, starting with TP-03, the first potential FDA approved drug for demodex blepharitis with blockbuster potential. Demodex blepharitis is a large and underserved market with approximately 25 million patients today in the US. As we develop TP-03 to treat DB, we're also actively progressing our pipeline into the clinic, notably within

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot